We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.625 | 3.85% | 16.875 | 16.75 | 17.00 | 17.375 | 15.75 | 16.25 | 4,313,408 | 16:06:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 30.8M | -21.7M | -0.0600 | -2.81 | 58.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/11/2024 10:01 | Few more for me on that drop. The share price down here is very close to the all time low which we hit on Friday of last week at around 16.25p so there really are not that many in profit around this level. There may be a few that sell for 10/15% I suppose and perhaps thats what we saw earlier. I am hopeful the recovery will speed up once these initial profit takers are out. At 18p to buy the share price is 25% cheaper than the recent £12M placing price of 24p where the directors put about £750k in. | parob | |
11/11/2024 09:33 | Full offer price of 18.4p being quoted now, the highest quote of the day. I'm not sure who the seller was but it feels like they are fully out now. I think that 720K trade on Thursday was the last from them. Recovery will speed up once this gets a little more noticed imo. | parob | |
11/11/2024 08:38 | Good to see strong interest this morning following Friday’s high volume day where we saw a lovely dragonfly doji candle form on the chart, hopefully signalling the bottom. The last time CREO did a placing (Feb 2023), the placing price was 20p and I think the lowest price the share price dropped to was 24/25p so demand was there. I think a large seller has provided a lovely entry opportunity here. It was 30% lower than the placing price (24p) at one point and even at 20p you’re still getting an almost 20% discount. Considering the price action on Friday I think that late 724K delayed sell I noticed from Thursday was the final amount from the seller. Added more today. | parob | |
10/11/2024 14:33 | Look at the volume since the insti started selling then look at the amount of shares held by each institution. I think the seller is done. Lovely daily candle formed on Friday. Here comes the bounce...... | malcolmz1 | |
09/11/2024 10:10 | If this has bottomed then I would hope to see a fairly quick recovery back to the placing price at the very least. Once the sale cash arrives in January that should give the price a further boost imo. | parob | |
08/11/2024 15:54 | I noticed a delayed 720,734 sale pop up earlier from yesterday at 16.5p, so perhaps that was the last amount from the seller. | parob | |
08/11/2024 15:48 | Huge volumes going through this afternoon now , maybe someone knows something ?? | gsargood | |
08/11/2024 15:28 | Back in today. Price is an absolute steal at this level imo. More than a 25% discount to recent placing price where directors put in about £750K.Liking the heavy volume, intraday reversal and dragonfly doji being created on the chart too. Hopefully bottom is in. | parob | |
08/11/2024 11:45 | Good luck, I believe the product is excellent but whether they can convince others that is more important. One of my worsed ever investments cash wise. Think the valuation is pretty much cash and consumables business. I've noticed that Edison didn't release any PR with the results. Guess either they are fed up with the company forecasts making them look stupid or Creo no longer think their puff pieces are any good. | dr biotech | |
08/11/2024 11:29 | The train wreck continues, but now I have bought back in it can stop hopefully. | peterrr3 | |
06/11/2024 12:21 | I would prefer they sell the rest of Europe and distribute the cash to us and put the company into hibernation until the medical trials are done or NICE reported. I can see management burning through the cash with very little to show in the intervening period on past performance unfortunately. | peterrr3 | |
06/11/2024 10:16 | Agreed , once the deal goes through will be sat on a pile of cash and in a good place very soon !! | gsargood | |
06/11/2024 10:09 | @1swifty I agree, the issue is that so many of these AIM stocks have so little interest in them currently that no real 2 way market exists. Patience should win through in the end on this one though. | bmcollins | |
06/11/2024 09:47 | Frustrating times with Creo. No news, share price dropping, lots of sells. Crazy fall since the impressive and positive news of stake sold in Creo Europe. If sale goes through cash available could be significant percentage of current market capital thus making current share price crazy low. | 1swifty | |
06/11/2024 08:40 | Placement group cutting losses today? I sold at .24 and took a minor bath in what now seems a stroke of genius. I expect the brokers will force some sort of positive update to stem the blood flow, so I will buy back in soon as the market cap moves down towards euro sale cash receipts. | peterrr3 | |
25/10/2024 09:24 | They have to seem at least a bit enthusiastic given the fees they are screwing out of the relationship. | peterrr3 | |
25/10/2024 07:13 | A piece in Citywire this morning states Deutsche has dropped its target level on Creo due to slow sales in H1 causing cash to be tighter than anticipated, but are still buyers, albeit less enthusiastic than previously. | bmcollins | |
23/10/2024 17:07 | The Texas trial design submitted June 21, recent update not yet recruiting. London submitted Feb 23, is recruiting and sorry I missed the latest update in Sep moving completion to Mar 26. | peterrr3 | |
22/10/2024 16:10 | Can't say I fully agree, they have been selling into the US for a while without completing the required clinical trials to validate the claims. Over promising sales and under delivering would have buried them in any market, not just AIM. Nasdaq is a wasteland of burnt biotech. When are the London trials going to be completed, years setting them up, no end in sight?. US trials not even recruiting yet. IMO Management are too overcompensated to feel the need to rush. | peterrr3 | |
22/10/2024 15:47 | AIM has become a graveyard for UK stocks. If this was listed in the US it would have double the market cap at least. They would be able to raise real money and really be able to drive sales and proof of concept. Here it is a hand to mouth existence. | the original goldbug | |
21/10/2024 10:10 | Unfortunately I got stopped out ! Love the tech though | bloomberg2 | |
20/10/2024 11:33 | I believe there is at least one fund that has to sell due to redemptions. Probably IHT related. Unfortunately it seems the analyst was right - but it was due to poor sales performance as much anything, so they can’t shift all the blame on external factors. I still hold though and hope they can succeed. | dr biotech | |
19/10/2024 10:28 | @Net Thanks for that post, it is helpful and does give "the other side" of the story, glum as it might look to holders who have watched a falling knife recently. I am still pretty optimistic, tbh, I rather buy into what the official comments say. | bmcollins |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions